Curative radiation therapy in prostate cancer

Harmenberg, Ulrika; Hamdy, Freddie C.; Widmark, Anders; Lennernäs, Bo; Nilsson, Sten

doi:10.3109/0284186x.2010.576115

Cited by 16 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By using image-guided radiation therapy or intensity modulated therapy, doses of 78–81 Gy may be administered while the healthy tissue surrounding the tumor is spared. Combinations with selected radiation boost regimens such as brachytherapy, may achieve doses of >116 Gy ( 5 ). However, 20–40% of patients receiving external irradiation therapy develop recurrent and more aggressive PCa within 10 years ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients

Andersson¹,

Rosestedt²,

Orlova³

2014

Oncology Letters

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common type of cancer among males. Human epidermal growth factor receptor type 2 (HER2) expression in PCa has been reported by several studies and its involvement in the progression towards androgen-independent PCa has been discussed. External irradiation is one of the existing therapies, which has been demonstrated to be efficient in combination with androgen deprivation therapy for the treatment of advanced PCa. However, 20–40% of patients develop recurrent and more aggressive PCa within 10 years. The current study investigates the involvement of HER2 in survival and radioresistance in PCa cells and we hypothesized that, by monitoring HER2 expression, treatment may be personalized. The PCa cell lines, LNCap, PC3 and DU-145, received a 6 Gy single dose of external irradiation. The number of PC3 cells was not affected by a single dose of radiation, whereas a 5-fold decrease in cell number was detected in LNCap (P<0.00001) and DU-145 (P<0.0001) cells. The HER2 expression in PC3 exhibited a significant increase post irradiation, however, the expression was stable in the remaining cell lines. The administration of trastuzumab post-irradiation resulted in a 2-fold decrease in the PC3 cell number, while the drug did not demonstrate additional effects in LNCap and DU-145 cells, when compared with that of irradiation treatment alone. The results of the present study demonstrated that an increase in membranous HER2 expression in response to external irradiation may indicate cell radioresistance. Furthermore, imaging of HER2 expression prior to and following external irradiation may present a step towards personalized therapy in PCa.

show abstract

Section: Introductionmentioning

confidence: 99%

Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients

Andersson¹,

Rosestedt²,

Orlova³

2014

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…In the USA, RARP is the most common surgical approach for PCa [118], and by 2014, it accounted for up to 90% of the total radical prostatectomies that were conducted [119]. In fact, radiotherapy is reported to be curative in 60% of men with localized PCa [120]. Compared with RP, the potential benefits of initial radiotherapy include its availability for surgically difficult patients or unresectable cancer lesions and the avoidance of substantial complications, such as urinary incontinence and erectile dysfunction, resulting from RP.…”

Section: Treatmentmentioning

confidence: 99%

Complexities of Prostate Cancer

Wasim

Lee

Kim

2022

IJMS

View full text Add to dashboard Cite

Prostate cancer has a long disease history and a wide variety and uncertainty in individual patients’ clinical progress. In recent years, we have seen a revolutionary advance in both prostate cancer patient care and in the research field. The power of deep sequencing has provided cistromic and transcriptomic knowledge of prostate cancer that has not discovered before. Our understanding of prostate cancer biology, from bedside and molecular imaging techniques, has also been greatly advanced. It is important that our current theragnostic schemes, including our diagnostic modalities, therapeutic responses, and the drugs available to target non-AR signaling should be improved. This review article discusses the current progress in the understanding of prostate cancer biology and the recent advances in diagnostic and therapeutic strategies.

show abstract

“…External radiotherapy, carried out as 39 fractions up to a total of 78 GY, is frequently used as the treatment of stage T1–T3 primary prostate cancer (Harmenberg et al , ). Radiotherapy is usually combined with androgen deprivation treatment, started 3 months before radiotherapy (Widmark et al , ), and for stage T3 patients androgen deprivations therapy may be given for up to 3 years.…”

Section: Introductionmentioning

confidence: 99%

Marital rehabilitation after prostate cancer – a matter of intimacy

Dieperink

Mark

Mikkelsen

2015

Int J of Uro Nursing

View full text Add to dashboard Cite

Prostate cancer is the most frequent male cancer disease in the western world. Sexual dysfunction is common after prostate cancer with radiation therapy and androgen deprivation therapy, but further research is needed to determine the lived experience of couples struggling with sexual dysfunction after treatment. The purpose of this study was to explore the lived experience of men and their partners experiencing sexual side effects after radiation therapy and androgen deprivation therapy for prostate cancer. In addition, to understand the role of a structured rehabilitation program on the couple's experience. Couples with persistent sexual problems were recruited among patients treated with radiotherapy or/and androgen deprivation therapy. Descriptive statistics were collected including age, race, education and work. Focus groups with each gender were conducted using open ended questions to encourage participants to talk about their experiences. Data were analyzed using Giorgi's phenomenological method. A total of eight couples were recruited, men age 67 years [standard deviation (SD) 6·3], women 65 years (SD 7·2). Results from the focus group interviews regarding marital relations were grouped in three themes: negative impact of sexual dysfunction on the relationship; other physical and psychological consequences of late adverse effects; communication issues and partner feelings of frustration. Results regarding the rehabilitation program were grouped in four themes: importance of peer support; importance of time and space for reflection; improved communication; optimism after rehabilitation. The couples in this study reported that the sexual side effects of prostate cancer treatment impacted their relationship and were problematic for both the men and their partners. The rehabilitation program improved the couples communication concerning sexual intimacy and issues related to prostate cancer treatment. It also offered a chance for peer support from others going through similar experiences and increased hope for navigating through sexual and intimacy issues in the future.

show abstract

Curative radiation therapy in prostate cancer

Cited by 16 publications

References 39 publications

Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients

Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients

Complexities of Prostate Cancer

Marital rehabilitation after prostate cancer – a matter of intimacy

Contact Info

Product

Resources

About